Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.3 USD | +0.82% | -0.69% | -13.69% |
14/05 | Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT |
03/05 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.69% | 340.34Cr | |
+7.38% | 11TCr | |
+11.13% | 11TCr | |
-12.46% | 2.22TCr | |
+0.44% | 2.13TCr | |
-4.18% | 1.9TCr | |
-37.85% | 1.85TCr | |
-8.79% | 1.68TCr | |
+37.54% | 1.25TCr | |
-24.36% | 808.97Cr |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Transcript : Ultragenyx Pharmaceutical Inc., Q3 2022 Earnings Call, Nov 02, 2022